RT Journal Article
SR Electronic
T1 High degree of implementation of intended management changes after <sup>68</sup>Ga-DOTATATE PET/CT imaging in patients with neuroendocrine tumors.<strong/>
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 172
OP 172
VO 58
IS supplement 1
A1 Calais, Jeremie
A1 Fendler, Wolfgang
A1 Eiber, Matthias
A1 Wolin, Edward
A1 Slavik, Roger
A1 Barrio, Martin
A1 Gupta, Pawan
A1 Quon, Andrew
A1 Schiepers, Christiaan
A1 Auerbach, Martin
A1 Czernin, Johannes
A1 Herrmann, Ken
YR 2017
UL http://jnm.snmjournals.org/content/58/supplement_1/172.abstract
AB 172Objectives: Somatostatin receptor (SSR) targeted PET/CT with 68Ga-DOTATATE (NETSPOT) is now FDA approved and reimbursed by the Centers for Medicare and Medicaid Services (CMS) for patients with neuroendocrine tumors. In a prospective study we have previously reported intended management changes as a consequence of 68Ga-DOTATATE PET/CT imaging in 60% of patients. In the current study we determined whether intended management changes were in fact implemented.Methods: Eighty-six patients with suspected SSR expressing NETs were prospectively enrolled to undergo 68Ga-DOTATATE PET/CT for initial or subsequent management decisions (NCT02174679). Referring physicians were asked to complete one questionnaire prior to the scan (Q1) to indicate the treatment plan without PET/CT information; one immediately after review of the imaging report to denote intended management changes (Q2); and one 6 months later (Q3) to verify whether intended changes were in fact implemented.Results: 68Ga-DOTATATE PET/CT resulted in intended management changes in 37/86 (43%) patients. These management changes were implemented in 31 of the 37 patients (84%). In detail, prior to acquisition of the PET/CT study 11 patients were scheduled to undergo surgery. Eight of these 11 patients (72%) were switched to conservative treatment as a consequence of 68Ga-DOTATATE. Conversely, 8/27 patients (30%) were moved from a non-surgical to a surgical management strategy. Eleven of 23 patients were switched from treatment to simple surveillance (48%). 66% of the patients who were initially scheduled for chemotherapy finally had other therapeutic options (4/6). In 6/37 patients (16 %) the intended management change was not implemented. Reasons for lack of implementation included: patient decision (n=1), second opinion (n=1), tumor board decision (n=1), unkown (n=3).Conclusion: This prospective referring physician survey i) confirms a substantial impact of 68Ga-DOTATATE PET/CT on patient management and ii) demonstrates a high degree of implementation of intended management changes after 68Ga-DOTATATE PET/CT imaging in patients with neuroendocrine tumors. Research Support: